Global Topical Steroids Market
Global Topical Steroids Market

Topical Steroids Comprehensive Study by Application (Hospitals, Dermatology Clinics, Pharmacies), By Treatment (Dermatitis, Insect stings, Eczema, Psoriasis, Others), By Potency Class (Low, Moderate, High, Ultra-high), By Formulation (Ointment, Gel, Creams, Others (Spray) Players and Region - Global Market Outlook to 2025

Topical Steroids Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jan 2020 Edition 211 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
A topical steroid is topical medications used to control dermatitis, Eczema, and numerous other skin conditions. It is generally used in the treatment of most dermatologic diseases and is applied to the skin for reducing inflammation and irritation. The process of action of topical steroid is extensive as it consists of anti-inflammatory, anti-mitotic, and immunosuppressive effects. These steroids are available in different types such as Ointment, Gel, Creams, and others. Moreover, it is accepted and used by hospitals, clinics, surgical centres. Therefore, the rising number of geriatric populace has boosted the market of Topical steroid.This growth is primarily driven by Increasing Concerns Related to Skin Diseases have also Boosted the Market, The rising number of geriatric populace and Consumption of topical steroid is growing..

Globally, a noticeable market trend is evident Increasing preference of topical steroid among the consumer and dermatologist.. Major Players, such as GlaxoSmithKline plc. (united kingdom), Sharp & Dohme Corp. (United States), Novartis (Switzerland), Pfizer (United States), Almirall (Spain), Bausch Health Companies Inc. (Canada), Actimis Pharmaceuticals (United States), Sanofi S.A. (France), LEO Pharma (Denmark) and AstraZeneca plc. (united kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
July 2018, Leo pharma acquired Bayer Prescription Dermatology unit to expand its lead into medical dermatology. The main aim of this acquisition is to embraces branded topical prescription treatments for acne, fungal skin infections and others. The company has produced its revenue (USD 10.4 billion in 2018) to expand its business presence across the international market.
In November 2018, lotion named Bryhali launched by Ortho Dermatologics for Plaque Psoriasis, a condition in which skin cells build up and form scales and itchy, dry patches. Because of Psoriasis diseases, people are suffering from serious clinical conditions such as cardiovascular and other non-communicable diseases.

Market Drivers
  • Increasing Concerns Related to Skin Diseases have also Boosted the Market
  • The rising number of geriatric populace
  • Consumption of topical steroid is growing.

Market Trend
  • Increasing preference of topical steroid among the consumer and dermatologist.

Restraints
  • Issues related to Allergic reactions using topical steroids

Opportunities
Increasing Demand from Developing Economies United Kingdom, Germany, the Netherlands, New Zealand. and Massive majority of the skin disease burden therefore implementing effective treatments targeted at those conditions boost the market demand
Challenges
Availability of substitute products and Adverse effects caused by these topical steroids

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Dermatology Clinics
  • Pharmacies
By By Treatment
  • Dermatitis
  • Insect stings
  • Eczema
  • Psoriasis
  • Others

By By Potency Class
  • Low
  • Moderate
  • High
  • Ultra-high

By By Formulation
  • Ointment
  • Gel
  • Creams
  • Others [Spray

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Concerns Related to Skin Diseases have also Boosted the Market
      • 3.2.2. The rising number of geriatric populace
      • 3.2.3. Consumption of topical steroid is growing.
    • 3.3. Market Challenges
      • 3.3.1. Availability of substitute products
      • 3.3.2. Adverse effects caused by these topical steroids
    • 3.4. Market Trends
      • 3.4.1. Increasing preference of topical steroid among the consumer and dermatologist.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Topical Steroids, by Application, By Treatment, By Potency Class, By Formulation and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Topical Steroids (Value)
      • 5.2.1. Global Topical Steroids by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Dermatology Clinics
        • 5.2.1.3. Pharmacies
      • 5.2.2. Global Topical Steroids by: By Treatment (Value)
        • 5.2.2.1. Dermatitis
        • 5.2.2.2. Insect stings
        • 5.2.2.3. Eczema
        • 5.2.2.4. Psoriasis
        • 5.2.2.5. Others
      • 5.2.3. Global Topical Steroids by: By Potency Class (Value)
        • 5.2.3.1. Low
        • 5.2.3.2. Moderate
        • 5.2.3.3. High
        • 5.2.3.4. Ultra-high
      • 5.2.4. Global Topical Steroids by: By Formulation (Value)
        • 5.2.4.1. Ointment
        • 5.2.4.2. Gel
        • 5.2.4.3. Creams
        • 5.2.4.4. Others [Spray
      • 5.2.5. Global Topical Steroids Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Topical Steroids: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (united kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sharp & Dohme Corp. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Almirall (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bausch Health Companies Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Actimis Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi S.A. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. LEO Pharma (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc. (united kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Topical Steroids Sale, by Application, By Treatment, By Potency Class, By Formulation and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Topical Steroids (Value)
      • 7.2.1. Global Topical Steroids by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Dermatology Clinics
        • 7.2.1.3. Pharmacies
      • 7.2.2. Global Topical Steroids by: By Treatment (Value)
        • 7.2.2.1. Dermatitis
        • 7.2.2.2. Insect stings
        • 7.2.2.3. Eczema
        • 7.2.2.4. Psoriasis
        • 7.2.2.5. Others
      • 7.2.3. Global Topical Steroids by: By Potency Class (Value)
        • 7.2.3.1. Low
        • 7.2.3.2. Moderate
        • 7.2.3.3. High
        • 7.2.3.4. Ultra-high
      • 7.2.4. Global Topical Steroids by: By Formulation (Value)
        • 7.2.4.1. Ointment
        • 7.2.4.2. Gel
        • 7.2.4.3. Creams
        • 7.2.4.4. Others [Spray
      • 7.2.5. Global Topical Steroids Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Topical Steroids: by Application(USD Million)
  • Table 2. Topical Steroids Hospitals , by Region USD Million (2014-2019)
  • Table 3. Topical Steroids Dermatology Clinics , by Region USD Million (2014-2019)
  • Table 4. Topical Steroids Pharmacies , by Region USD Million (2014-2019)
  • Table 5. Topical Steroids: by By Treatment(USD Million)
  • Table 6. Topical Steroids Dermatitis , by Region USD Million (2014-2019)
  • Table 7. Topical Steroids Insect stings , by Region USD Million (2014-2019)
  • Table 8. Topical Steroids Eczema , by Region USD Million (2014-2019)
  • Table 9. Topical Steroids Psoriasis , by Region USD Million (2014-2019)
  • Table 10. Topical Steroids Others , by Region USD Million (2014-2019)
  • Table 11. Topical Steroids: by By Potency Class(USD Million)
  • Table 12. Topical Steroids Low , by Region USD Million (2014-2019)
  • Table 13. Topical Steroids Moderate , by Region USD Million (2014-2019)
  • Table 14. Topical Steroids High , by Region USD Million (2014-2019)
  • Table 15. Topical Steroids Ultra-high , by Region USD Million (2014-2019)
  • Table 16. Topical Steroids: by By Formulation(USD Million)
  • Table 17. Topical Steroids Ointment , by Region USD Million (2014-2019)
  • Table 18. Topical Steroids Gel , by Region USD Million (2014-2019)
  • Table 19. Topical Steroids Creams , by Region USD Million (2014-2019)
  • Table 20. Topical Steroids Others [Spray , by Region USD Million (2014-2019)
  • Table 21. South America Topical Steroids, by Country USD Million (2014-2019)
  • Table 22. South America Topical Steroids, by Application USD Million (2014-2019)
  • Table 23. South America Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 24. South America Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 25. South America Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 26. Brazil Topical Steroids, by Application USD Million (2014-2019)
  • Table 27. Brazil Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 28. Brazil Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 29. Brazil Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 30. Argentina Topical Steroids, by Application USD Million (2014-2019)
  • Table 31. Argentina Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 32. Argentina Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 33. Argentina Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 34. Rest of South America Topical Steroids, by Application USD Million (2014-2019)
  • Table 35. Rest of South America Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 36. Rest of South America Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 37. Rest of South America Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 38. Asia Pacific Topical Steroids, by Country USD Million (2014-2019)
  • Table 39. Asia Pacific Topical Steroids, by Application USD Million (2014-2019)
  • Table 40. Asia Pacific Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 41. Asia Pacific Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 42. Asia Pacific Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 43. China Topical Steroids, by Application USD Million (2014-2019)
  • Table 44. China Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 45. China Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 46. China Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 47. Japan Topical Steroids, by Application USD Million (2014-2019)
  • Table 48. Japan Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 49. Japan Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 50. Japan Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 51. India Topical Steroids, by Application USD Million (2014-2019)
  • Table 52. India Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 53. India Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 54. India Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 55. South Korea Topical Steroids, by Application USD Million (2014-2019)
  • Table 56. South Korea Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 57. South Korea Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 58. South Korea Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 59. Taiwan Topical Steroids, by Application USD Million (2014-2019)
  • Table 60. Taiwan Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 61. Taiwan Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 62. Taiwan Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 63. Australia Topical Steroids, by Application USD Million (2014-2019)
  • Table 64. Australia Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 65. Australia Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 66. Australia Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Topical Steroids, by Application USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 71. Europe Topical Steroids, by Country USD Million (2014-2019)
  • Table 72. Europe Topical Steroids, by Application USD Million (2014-2019)
  • Table 73. Europe Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 74. Europe Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 75. Europe Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 76. Germany Topical Steroids, by Application USD Million (2014-2019)
  • Table 77. Germany Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 78. Germany Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 79. Germany Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 80. France Topical Steroids, by Application USD Million (2014-2019)
  • Table 81. France Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 82. France Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 83. France Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 84. Italy Topical Steroids, by Application USD Million (2014-2019)
  • Table 85. Italy Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 86. Italy Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 87. Italy Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 88. United Kingdom Topical Steroids, by Application USD Million (2014-2019)
  • Table 89. United Kingdom Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 90. United Kingdom Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 91. United Kingdom Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 92. Netherlands Topical Steroids, by Application USD Million (2014-2019)
  • Table 93. Netherlands Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 94. Netherlands Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 95. Netherlands Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 96. Rest of Europe Topical Steroids, by Application USD Million (2014-2019)
  • Table 97. Rest of Europe Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 98. Rest of Europe Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 99. Rest of Europe Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 100. MEA Topical Steroids, by Country USD Million (2014-2019)
  • Table 101. MEA Topical Steroids, by Application USD Million (2014-2019)
  • Table 102. MEA Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 103. MEA Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 104. MEA Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 105. Middle East Topical Steroids, by Application USD Million (2014-2019)
  • Table 106. Middle East Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 107. Middle East Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 108. Middle East Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 109. Africa Topical Steroids, by Application USD Million (2014-2019)
  • Table 110. Africa Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 111. Africa Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 112. Africa Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 113. North America Topical Steroids, by Country USD Million (2014-2019)
  • Table 114. North America Topical Steroids, by Application USD Million (2014-2019)
  • Table 115. North America Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 116. North America Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 117. North America Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 118. United States Topical Steroids, by Application USD Million (2014-2019)
  • Table 119. United States Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 120. United States Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 121. United States Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 122. Canada Topical Steroids, by Application USD Million (2014-2019)
  • Table 123. Canada Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 124. Canada Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 125. Canada Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 126. Mexico Topical Steroids, by Application USD Million (2014-2019)
  • Table 127. Mexico Topical Steroids, by By Treatment USD Million (2014-2019)
  • Table 128. Mexico Topical Steroids, by By Potency Class USD Million (2014-2019)
  • Table 129. Mexico Topical Steroids, by By Formulation USD Million (2014-2019)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Topical Steroids: by Application(USD Million)
  • Table 141. Topical Steroids Hospitals , by Region USD Million (2020-2025)
  • Table 142. Topical Steroids Dermatology Clinics , by Region USD Million (2020-2025)
  • Table 143. Topical Steroids Pharmacies , by Region USD Million (2020-2025)
  • Table 144. Topical Steroids: by By Treatment(USD Million)
  • Table 145. Topical Steroids Dermatitis , by Region USD Million (2020-2025)
  • Table 146. Topical Steroids Insect stings , by Region USD Million (2020-2025)
  • Table 147. Topical Steroids Eczema , by Region USD Million (2020-2025)
  • Table 148. Topical Steroids Psoriasis , by Region USD Million (2020-2025)
  • Table 149. Topical Steroids Others , by Region USD Million (2020-2025)
  • Table 150. Topical Steroids: by By Potency Class(USD Million)
  • Table 151. Topical Steroids Low , by Region USD Million (2020-2025)
  • Table 152. Topical Steroids Moderate , by Region USD Million (2020-2025)
  • Table 153. Topical Steroids High , by Region USD Million (2020-2025)
  • Table 154. Topical Steroids Ultra-high , by Region USD Million (2020-2025)
  • Table 155. Topical Steroids: by By Formulation(USD Million)
  • Table 156. Topical Steroids Ointment , by Region USD Million (2020-2025)
  • Table 157. Topical Steroids Gel , by Region USD Million (2020-2025)
  • Table 158. Topical Steroids Creams , by Region USD Million (2020-2025)
  • Table 159. Topical Steroids Others [Spray , by Region USD Million (2020-2025)
  • Table 160. South America Topical Steroids, by Country USD Million (2020-2025)
  • Table 161. South America Topical Steroids, by Application USD Million (2020-2025)
  • Table 162. South America Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 163. South America Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 164. South America Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 165. Brazil Topical Steroids, by Application USD Million (2020-2025)
  • Table 166. Brazil Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 167. Brazil Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 168. Brazil Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 169. Argentina Topical Steroids, by Application USD Million (2020-2025)
  • Table 170. Argentina Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 171. Argentina Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 172. Argentina Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 173. Rest of South America Topical Steroids, by Application USD Million (2020-2025)
  • Table 174. Rest of South America Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 175. Rest of South America Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 176. Rest of South America Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 177. Asia Pacific Topical Steroids, by Country USD Million (2020-2025)
  • Table 178. Asia Pacific Topical Steroids, by Application USD Million (2020-2025)
  • Table 179. Asia Pacific Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 180. Asia Pacific Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 181. Asia Pacific Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 182. China Topical Steroids, by Application USD Million (2020-2025)
  • Table 183. China Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 184. China Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 185. China Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 186. Japan Topical Steroids, by Application USD Million (2020-2025)
  • Table 187. Japan Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 188. Japan Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 189. Japan Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 190. India Topical Steroids, by Application USD Million (2020-2025)
  • Table 191. India Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 192. India Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 193. India Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 194. South Korea Topical Steroids, by Application USD Million (2020-2025)
  • Table 195. South Korea Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 196. South Korea Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 197. South Korea Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 198. Taiwan Topical Steroids, by Application USD Million (2020-2025)
  • Table 199. Taiwan Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 200. Taiwan Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 201. Taiwan Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 202. Australia Topical Steroids, by Application USD Million (2020-2025)
  • Table 203. Australia Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 204. Australia Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 205. Australia Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 206. Rest of Asia-Pacific Topical Steroids, by Application USD Million (2020-2025)
  • Table 207. Rest of Asia-Pacific Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 208. Rest of Asia-Pacific Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 209. Rest of Asia-Pacific Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 210. Europe Topical Steroids, by Country USD Million (2020-2025)
  • Table 211. Europe Topical Steroids, by Application USD Million (2020-2025)
  • Table 212. Europe Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 213. Europe Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 214. Europe Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 215. Germany Topical Steroids, by Application USD Million (2020-2025)
  • Table 216. Germany Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 217. Germany Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 218. Germany Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 219. France Topical Steroids, by Application USD Million (2020-2025)
  • Table 220. France Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 221. France Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 222. France Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 223. Italy Topical Steroids, by Application USD Million (2020-2025)
  • Table 224. Italy Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 225. Italy Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 226. Italy Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 227. United Kingdom Topical Steroids, by Application USD Million (2020-2025)
  • Table 228. United Kingdom Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 229. United Kingdom Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 230. United Kingdom Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 231. Netherlands Topical Steroids, by Application USD Million (2020-2025)
  • Table 232. Netherlands Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 233. Netherlands Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 234. Netherlands Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 235. Rest of Europe Topical Steroids, by Application USD Million (2020-2025)
  • Table 236. Rest of Europe Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 237. Rest of Europe Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 238. Rest of Europe Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 239. MEA Topical Steroids, by Country USD Million (2020-2025)
  • Table 240. MEA Topical Steroids, by Application USD Million (2020-2025)
  • Table 241. MEA Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 242. MEA Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 243. MEA Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 244. Middle East Topical Steroids, by Application USD Million (2020-2025)
  • Table 245. Middle East Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 246. Middle East Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 247. Middle East Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 248. Africa Topical Steroids, by Application USD Million (2020-2025)
  • Table 249. Africa Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 250. Africa Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 251. Africa Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 252. North America Topical Steroids, by Country USD Million (2020-2025)
  • Table 253. North America Topical Steroids, by Application USD Million (2020-2025)
  • Table 254. North America Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 255. North America Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 256. North America Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 257. United States Topical Steroids, by Application USD Million (2020-2025)
  • Table 258. United States Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 259. United States Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 260. United States Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 261. Canada Topical Steroids, by Application USD Million (2020-2025)
  • Table 262. Canada Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 263. Canada Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 264. Canada Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 265. Mexico Topical Steroids, by Application USD Million (2020-2025)
  • Table 266. Mexico Topical Steroids, by By Treatment USD Million (2020-2025)
  • Table 267. Mexico Topical Steroids, by By Potency Class USD Million (2020-2025)
  • Table 268. Mexico Topical Steroids, by By Formulation USD Million (2020-2025)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Topical Steroids: by Application USD Million (2014-2019)
  • Figure 5. Global Topical Steroids: by By Treatment USD Million (2014-2019)
  • Figure 6. Global Topical Steroids: by By Potency Class USD Million (2014-2019)
  • Figure 7. Global Topical Steroids: by By Formulation USD Million (2014-2019)
  • Figure 8. South America Topical Steroids Share (%), by Country
  • Figure 9. Asia Pacific Topical Steroids Share (%), by Country
  • Figure 10. Europe Topical Steroids Share (%), by Country
  • Figure 11. MEA Topical Steroids Share (%), by Country
  • Figure 12. North America Topical Steroids Share (%), by Country
  • Figure 13. Global Topical Steroids share by Players 2019 (%)
  • Figure 14. Global Topical Steroids share by Players (Top 3) 2019(%)
  • Figure 15. Global Topical Steroids share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc. (united kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc. (united kingdom) Revenue: by Geography 2019
  • Figure 19. Sharp & Dohme Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Sharp & Dohme Corp. (United States) Revenue: by Geography 2019
  • Figure 21. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2019
  • Figure 25. Almirall (Spain) Revenue, Net Income and Gross profit
  • Figure 26. Almirall (Spain) Revenue: by Geography 2019
  • Figure 27. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2019
  • Figure 29. Actimis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Actimis Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 31. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 33. LEO Pharma (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. LEO Pharma (Denmark) Revenue: by Geography 2019
  • Figure 35. AstraZeneca plc. (united kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca plc. (united kingdom) Revenue: by Geography 2019
  • Figure 37. Global Topical Steroids: by Application USD Million (2020-2025)
  • Figure 38. Global Topical Steroids: by By Treatment USD Million (2020-2025)
  • Figure 39. Global Topical Steroids: by By Potency Class USD Million (2020-2025)
  • Figure 40. Global Topical Steroids: by By Formulation USD Million (2020-2025)
  • Figure 41. South America Topical Steroids Share (%), by Country
  • Figure 42. Asia Pacific Topical Steroids Share (%), by Country
  • Figure 43. Europe Topical Steroids Share (%), by Country
  • Figure 44. MEA Topical Steroids Share (%), by Country
  • Figure 45. North America Topical Steroids Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc. (united kingdom)
  • Sharp & Dohme Corp. (United States)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Almirall (Spain)
  • Bausch Health Companies Inc. (Canada)
  • Actimis Pharmaceuticals (United States)
  • Sanofi S.A. (France)
  • LEO Pharma (Denmark)
  • AstraZeneca plc. (united kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation